# EDGAR Filing Document

**Accession Number:** 0001162461
**File Stem:** 0001628280-23-000735
**Filing Date:** 2023-1
**Character Count:** 8389
**Document Hash:** efcc8d5b2932978038d8ab1d00bc0cd0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-23-000735.hdr.sgml**: 20230109

**ACCESSION NUMBER**: 0001628280-23-000735

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20230109

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230109

**DATE AS OF CHANGE**: 20230109

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CUTERA INC
- **CENTRAL INDEX KEY:** 0001162461
- **STANDARD INDUSTRIAL CLASSIFICATION:** ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
- **IRS NUMBER:** 770492262
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-50644
- **FILM NUMBER:** 23516759

**BUSINESS ADDRESS:**
- **STREET 1:** 3240 BAYSHORE BOULEVARD
- **CITY:** BRISBANE
- **STATE:** CA
- **ZIP:** 94005
- **BUSINESS PHONE:** 94005

**MAIL ADDRESS:**
- **STREET 1:** 3240 BAYSHORE BOULEVARD
- **CITY:** BRISBANE
- **STATE:** CA
- **ZIP:** 94005

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ALTUS MEDICAL INC
- **DATE OF NAME CHANGE:** 20011119

?xml version="1.0" ? cutr-20230109

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

 

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of**

**the Securities Exchange Act of 1934**

January 9, 2023

Date of Report (date of earliest event reported)

![cutr-20230109_g1.jpg](cutr-20230109_g1.jpg)

 

**Cutera, Inc.**

**(Exact name of Registrant as specified in its charter)**

 

---

| | | |
|:---|:---|:---|
| **Delaware** | **000-50644** | **77-0492262** |
| **(State or other jurisdiction of<br>incorporation)** | **(Commission File Number)** | **(I.R.S. Employer<br>Identification Number)** |

---

**3240 Bayshore Blvd.**

**Brisbane, California 94005**

**(Address of principal executive offices)**

&nbsp;&nbsp;&nbsp;&nbsp;**(415) 657-5500**

**(Registrant**'**s telephone number, including area code)**

**N/A**

**(Former name or former address, if changed since last report)**

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock ($0.001 par value) | CUTR | The NASDAQ Stock Market, LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

------

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 2.02. Results of Operations and Financial Condition.**

On January 9, 2023, Cutera, Inc. (the "Company") issued a press release disclosing selected preliminary, unaudited financial results for the full-year ended December 31, 2022. A copy of the Company's press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

**Item 7.01. Regulation FD Disclosure.**

On January 9, 2023, the Company issued a press release discussed above in Item 2.02 of this Current Report on Form 8-K. A copy of the press release is attached hereto as Exhibit 99.1. This information in Items 2.02 and 7.01 of this report is being furnished, not filed, for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and pursuant to General Instruction B.2 of Form 8-K, will not be incorporated by reference into any filing under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference.

**Item 9.01. Financial Statements and Exhibits.** 

**(d)Exhibits.**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | <u>[Press Release of Cutera, Inc. dated as of](exhibit9918k1923.htm)[January](exhibit9918k1923.htm)[9](exhibit9918k1923.htm)[, 202](exhibit9918k1923.htm)[3](exhibit9918k1923.htm)[.](exhibit9918k1923.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| | CUTERA, INC. |
| Date: January 9, 2023 | */s/ ROHAN SETH* |
| | Rohan Seth |
| | Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![cuteralogoa.jpg](cuteralogoa.jpg)

**Cutera Announces Preliminary Unaudited Financial Results for Full-Year 2022** 

BRISBANE, California, January 9, 2023 ─ Cutera, Inc. (Nasdaq: CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, today announced certain preliminary, unaudited financial results for the year ended December 31, 2022. These results are subject to the completion of the Company's year-end financial reporting processes, reviews, and audit.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Company expects to report revenue in the range of $252 million to $253 million for full-year 2022, growing 15% to 16% over the prior year on a constant currency basis versus prior guidance of $255 million to $260 million.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Company plans to release full results for the fourth quarter, and fiscal year, ended December 31, 2022 after market close on February 28, 2023. The Company will host a conference call to discuss these results on that date at 4:30 p.m. Eastern Time. Additional details regarding the webcast and conference call dial-in information will follow.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Cutera Management – Dave Mowry, CEO; J. Daniel Plants, Executive Chairman; and Rohan Seth, CFO – will be hosting a series of individual investor meetings over the course of January 10 – 12, 2023 at the Nasdaq Offices at 505 Howard St, Suite 4200 in downtown San Francisco.

**About Cutera, Inc.** 

Brisbane, California-based Cutera is a leading provider of aesthetic and dermatology solutions for practitioners worldwide. Since 1998, Cutera has been developing innovative, easy-to-use products that harness the power of science and nature to enable medical practitioners to offer safe and effective treatments to their patients. For more information, call +1-415-657-5500 or 1-888-4CUTERA or visit www.cutera.com

Cutera, Inc. has not completed the preparation of its financial statements for the fourth quarter or full year of 2022. The revenue ranges presented in this news release for the year ended Dec. 31, 2022, are preliminary and unaudited and are subject to change as the Company completes its financial results for the fourth quarter of 2022. The Company is in the process of completing its customary year-end close and review procedures as of and for the year ended Dec. 31, 2022, and there can be no assurance that the final results for this period will not differ from these estimates. During the course of the preparation of the consolidated financial statements and related notes as of and for the year ended Dec. 31, 2022, the Company or its independent registered public accountants may identify items that could cause the final reported results to be materially different from the preliminary financial estimates presented herein.

**Cutera, Inc.**

Greg Barker

VP, Corporate FP&A

415-657-5500

IR@cutera.com

<br>